IGC — IGC Pharma, Inc.
$0.2460-0.69%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for IGC in the TickerWise workspace.
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: AMEX
- Employees: 67
- Website: https://igcpharma.com
Latest SEC filings for IGC
Latest IGC news
- IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment Read article
- IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.